. home.aspx



Acorda Snags Approval for New Treatment of OFF Episodes of Parkinson’s Disease

December 26, 2018 / Alex Keown

Acorda Therapeutics can breathe a bit easier. The U.S. Food and Drug Administration (FDA) approved Inbrija, the first inhaled formula of levodopa (L-dopa) for the intermittent treatment of OFF episodes in Parkinson’s disease patients. The approval came about two weeks before its PUDFA date. The regulatory agency was initially expected to make a ruling on Inbrija in October, but the FDA extended the review of the drug to Jan. 5. 2019. In September, Acorda said the delay was due to the FDA’s requests for additional information on chemistry, manufacturing and controls. The FDA determined the submissions “constitute a major amendment” and will take additional time to review, Acorda said in September. However, now the FDA has completed its review and given the green-light to Inbrija. The approval is for Parkinson’s patients who are already being treated with carbidopa/levodopa. There are approximately 350,000 people in the U.S. who are challenged by OFF periods...